Lonza Group stock edges lower as investors digest recent earnings
Published on 09/13/2026 at 14:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group stock (ISIN CH0013841017) was quoted at CHF 588.60 in recent trading on SIX Swiss Exchange as of September 13, 2026, leaving the shares slightly below their recent 52-week high and reflecting a modest day-on-day move for investors watching the Swiss life sciences supplier.
Share performance and valuation backdrop
On September 13, 2026, data from a German stock portal showed Lonza Group changing hands at EUR 588.60 in Frankfurt trading, with the intraday low and high at EUR 570.00 and EUR 588.60, respectively, and a marginal daily decline of 0.10 % from the prior close of EUR 588.20. According to finanzen.net, this trading snapshot corresponds to a market capitalization of about EUR 41.61 billion, underlining Lonza's positioning among Europe’s large-cap life sciences and contract manufacturing players.
The same overview indicates that Lonza's 52-week high stands at EUR 571.60 and its 52-week low at EUR 499.20, which implies that the recent EUR 588.60 Frankfurt price converted to Swiss francs leaves the stock trading close to, but not materially above, its high over the last year and well above the low point of that period. For retail investors, that range highlights how the share has recovered from weaker phases while still leaving room for further upside or downside depending on upcoming results and sector sentiment.
Recent earnings, margins and dividend profile
While the latest interim report is not directly visible in the recent snapshot, the finanzen.net overview aggregates Lonza Group’s earnings trajectory and dividend profile, giving investors a sense of how fundamentals have developed over the most recent fiscal years. According to finanzen.net, Lonza reported earnings per share of CHF 8.93 in fiscal year 2024 versus negative earnings per share of CHF -3.93 in fiscal year 2025, illustrating how one-off effects or a weaker operating environment significantly affected profitability in that year.
For context, the same data set shows an expected rebound in earnings, with consensus estimates pointing to earnings per share of CHF 18.21 for 2026 and CHF 21.66 for 2027, which would more than double reported EPS from fiscal year 2024 if achieved. These forward figures are estimates rather than reported numbers but they highlight how analysts expect Lonza’s margins and utilization rates to improve as new manufacturing capacities ramp up and demand for biologics and small-molecule services stabilizes.
The dividend profile also reflects Lonza’s ambition to deliver shareholder returns alongside growth. As per the dividend table in the finanzen.net overview, Lonza paid a dividend of CHF 4.00 for fiscal year 2024 and is expected to lift that payout to CHF 5.00 for fiscal year 2025, with further increases to CHF 5.62 in 2026 and CHF 6.55 in 2027, assuming board proposals and shareholder approvals in line with consensus. Historically, the dividend yield based on the share price stood at roughly 0.75 % for fiscal year 2024 and is projected to rise toward 1.01 % for 2026 as payouts grow faster than the current price, offering investors a modest but growing income component.
Growth expectations and risk factors
The valuation backdrop for Lonza Group is shaped by these earnings expectations. According to forward price-earnings ratios compiled by finanzen.net, the stock’s price-earnings ratio based on reported earnings reached 59.96 for fiscal year 2024, reflecting a premium valuation when growth was still largely priced into the shares. For the 2026 estimate, the expected price-earnings ratio moderates to around 30.60, with further compression to 25.74 in 2027 and 22.13 in 2028 if earnings grow as anticipated, suggesting that investors are banking on a recovery in profitability to justify the current market capitalization.
From an investor perspective, the key risk is that Lonza fails to deliver the earnings and margin improvements embedded in these projections. Capacity expansions require high upfront investments, and any delay in customer ramp-ups or pricing pressure in contract manufacturing could leave earnings per share and free cash flow below the levels implied by consensus. In that case, the stock’s still-elevated valuation multiples could come under pressure, particularly if broader life sciences indices or the STOXX Europe 600 Health Care sector re-rate downward at the same time.
On the other hand, if Lonza manages to execute its pipeline of new contracts, maintain strong utilization rates and move past the negative earnings seen in fiscal year 2025, the projected EPS growth to CHF 18.21 in 2026 and CHF 21.66 in 2027 could reinforce investor confidence. That scenario would not only support the premium valuation but also make the planned dividend increases more sustainable, potentially pushing the dividend yield beyond 1.18 % in 2027 as indicated by the finanzen.net data.
Stock level and investor takeaway
As of the most recent available data point on September 13, 2026, Lonza Group stock on SIX Swiss Exchange is trading close to its 52-week high in Swiss franc terms, with the Frankfurt EUR quote near EUR 588.60 and a market capitalization of about EUR 41.61 billion. The share price thus reflects the market’s expectation of a recovery from the negative earnings recorded in fiscal year 2025, while leaving limited room for disappointment on future results and sector demand.
Lonza Group stock key data
- Company: Lonza Group Ltd.
- ISIN: CH0013841017
- Ticker: LONN
- Trading venue: SIX Swiss Exchange
- Price (as of September 13, 2026): 588.60 CHF
- Market capitalization: 41.61 billion EUR (as of September 13, 2026)
- Sector / Industry: Health care / Life sciences tools and contract manufacturing
- Index membership: SMI
